Table 2.
Case-crossover analysis of testosterone injections and all testosterone receipt with acute cardiovascular and cerebrovascular events, 30-day gap between exposure and control periods
| Testosterone injections | Any testosterone receipt** | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Dataset | Outcome | Injections during focal window, N | Injections during referent windows, N | OR | (95% CI) | Receipt during focal window, N | Receipt during referent windows, N | OR | (95% CI) |
| MarketScan | MI | 150 | 857 | 1.06 | (0.87, 1.29) | 266 | 1,602 | 1.00 | (0.87, 1.15) |
| Stroke | 115 | 700 | 0.98 | (0.79, 1.22) | 251 | 1,444 | 1.05 | (0.91, 1.21) | |
| Composite* | 296 | 1,805 | 0.98 | (0.86, 1.12) | 601 | 3,579 | 1.01 | (0.92, 1.11) | |
| Medicare | MI | 26 | 123 | 1.36 | (0.84, 2.21) | 32 | 175 | 1.12 | (0.74, 1.69) |
| Stroke | 28 | 120 | 1.53 | (0.96, 2.43) | 39 | 186 | 1.31 | (0.90, 1.92) | |
| Composite* | 65 | 291 | 1.45 | (1.07, 1.98) | 86 | 426 | 1.26 | (0.98, 1.63) | |
Abbreviations: OR, odds ratio; CI, confidence interval
*
Composite outcome consists of myocardial infarction, stroke, or unstable angina
**
Testosterone injection, implantation, or pharmacy dispensing